Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
Jeanne G. Vaughn, NP
Advertisement
Articles by Jeanne G. Vaughn, NP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5